Effects of Chemotherapy, Gastric Adenocarcinoma, Gastric Cancer, Toxicity Due to Chemotherapy
Conditions
Keywords
Gastric cancer, Gastroesophageal junction cancer, Locally advanced, Perioperative chemotherapy, Triplet
Brief summary
The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.
Detailed description
The study is an open-label, single-arm, single-country and multi-center phase II investigator-initiated trial. Patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who enroll the trial will receive perioperative chemotherapy with LOTS (14 days as a cycle) 4 cycles every 2 weeks, followed by operation and another 4 cycles every 2 weeks post-operatively. The primary outcome is pathological response or curative resection rate. The secondary outcome includes recurrence-free survival, overall survival, disease control rate, protocol completion rate and adverse events.
Interventions
DRUGleucovorin, oxaliplatin, docetaxel, S-1
Perioperative chemotherapy with LOTS
Sponsors
TTY Biopharm
Kaohsiung Veterans General Hospital.
Taipei Veterans General Hospital, Taiwan
China Medical University Hospital
National Cheng-Kung University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open-label
Intervention model description
Single intervention arm with trial treatment
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Subjects have histologically-confirmed gastric or gastroesophageal junction (classified as Siewert type III) adenocarcinoma with a clinical stage of T3 or above, lymph node involvement (N+) or both according to American Joint Cancer Committee staging system, 8th edition (AJCC 8th). 2. Subjects present with at least one measurable lesion which can be accurately assessed by conventional techniques at least 2.0 cm or 1.0 cm by computed tomography (CT) or magnetic resonance imaging (MRI). 3. Subjects have a lymph node-positive disease in which that at least one of the nodes with a diameter greater or equal to 0.8 cm in the long axis. If subjects do not have a node-positive disease, a clinical stage of T3 or above and a measurable tumor is required for inclusion. 4. Subjects are above 20 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ≤1, have a life expectancy \>3 months, have surgically resectable disease and are physically competent and willing to receive a curative operation. 5. Subjects have adequate organ functions, including bone marrow reserve with a leukocyte count ≥3,000 /µL and platelet count ≥100,000 /µL, hepatic reserve with a serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times of upper limits and total bilirubin ≤2.0 mg/dL, renal reserve with a creatinine clearance ≥60 mL/min and cardiac reserve with a left ventricular ejection fraction (LVEF) ≥50% by echocardiography at baseline. 6. Subjects have, or agree to establish a vascular access that permits systemic intravenous chemotherapy and are capable of ingesting capsules per oral. 7. Subjects with reproductive potentials are willing to accept contraceptive measures during the trial. 8. Subjects are functionally and cognitively capable to be informed of the trial contents and objectives (including obtaining blood and tumor tissue for the trial investigation), and agree to sign the written consent for enrollment.
Exclusion criteria
1. Subjects have metastatic (M1, including washing cytology positive for peritoneal carcinomatosis), recurrent gastric/gastroesophageal junction cancer (defined by an interval time less than five years from the current diagnosis to the prior initial disease), or any other underlying primary malignancies excluding carcinoma in situ or resectable skin cancer. 2. Subjects have received chemotherapies within 2 years, or a major abdominal surgery or radiotherapy within 4 weeks before the trial enrollment. 3. Subjects are known to be allergic to any of the studied chemotherapeutics. 4. Subjects have underlying chronic illnesses, including cardiopulmonary diseases, ischemic heart disease, inflammatory bowel disease, poorly-controlled diabetes mellitus, liver cirrhosis and/or peripheral neuropathy of any etiologies. 5. Subjects have active bacterial, viral, fungal or mycobacterial infections that require systemic therapy, including active infection with human immunodeficiency virus (HIV), hepatitis B or C virus (HBV or HCV) 6. Subjects are planning to conceive or already in pregnancy or breastfeeding. 7. Subjects are currently participating in any other clinical trials or studies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological response | after pre-operative chemotherapy and curative surgery (Week 11 to 13) | the tumor pathological response after pre-operative chemotherapy with LOTS plus curative surgery. The pathological response is defined by tumor evaluation of complete, partial or no response according to tumor regression grading (TRG) |
| Curative resection rate | after pre-operative chemotherapy and curative surgery (Week 11 to 13) | the rate of margin-free (R0) resection in the absence of macro- or microscopic residual tumors remaining at the primary tumor bed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate | From date of the initiation of trial treatment until the date of recurrence/death events, withdrawal from the trial at any causes, termination/completion of the trial, whichever came first, assessed up to 48 months | the rate of patients remaining in disease control (complete, partial response and stable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines version 1.1) lasting at least three months |
| Recurrence-free survival | From date of the initiation of trial treatment until the date of disease recurrence, progression or death at any causes, whichever came first, assessed up to 48 months | the time interval from the initiation of trial treatment to disease recurrence, progression or death at any causes |
| Treatment-emergent adverse event rate | From date of the initiation of trial treatment until the date of recurrence/death events, withdrawal from the trial at any causes, termination/completion of the trial, whichever came first, assessed up to 48 months | the rate of protocol treatment-emergent adverse events, as graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Protocol completion rate | From date of the initiation of trial treatment until the date of recurrence/death events, withdrawal from the trial at any causes, termination/completion of the trial, whichever came first, assessed up to 48 months | the rate of patients completing the pre-specified protocol treatment |
| Overall survival | From date of the initiation of trial treatment until the date of death at any causes, assessed up to 48 months | the time interval from the initiation of trial treatment to death at any causes |
Countries
Taiwan
Contacts
Primary ContactClinical Trial Center, National Cheng-Kung University Hospital
Backup ContactChih Chieh Yen, M.D.
Outcome results
None listed